Advancing clinical research and making the discoveries necessary to fight and overcome rhabdomyosarcoma effectively, and with minimal long term side effects, is critical to our strategy.
Ensuring that the research has concrete outputs that can be translated to provide the greatest benefit to patients diagnosed around the world in the future is also vital.
We work closely with a network of expert scientists and clinicians who focus on rhabdomyosarcoma. These individuals are based at major research institutions and leading paediatric cancer hospitals. They include, the Institute of Cancer Research (ICR), the University of Birmingham, Wellcome Sanger Institute, The Royal Marsden, Great Ormond Street Hospital and the UCL Great Ormond Street Institute of Child Health.